KAPA · Kairos Pharma, LTD. · Executive Compensation
$0.56
+0.01 (+2.67%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has experienced recurring losses from operations since inception and incurred a net loss of $3,042 and used cash in operations of $2,048 during the six months ended June 30, 2026. These factors raise substantial doubt about the Company's ability to continue as a going concern. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$1.89M
Shares
3.39M
Volume · Oct 23
112.9K
Avg daily vol (38 sessions)
568.46K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Dr. Rahul Singhvi | director of the Board | Appointed | 2024-12-13 |
Leadership
- John S. Yu CEO
- Doug Samuelson CFO
- Dr. Rahul Singhvi Board Member
- Hansoo Michael Keyoung Board Member
- Hyun W. Bae Board Member
- Rahul Sighvi Board Member